TNFRSF9 and lymphoma: We have previously demonstrated that antibodies targeting 4-1BB synergize with rituximab (anti-CD20) and trastuzumab (anti-HER2) to clear tumors in murine xenograft models of lymphoma and breast cancer [25, 26].